<DOC>
	<DOCNO>NCT00607347</DOCNO>
	<brief_summary>The researcher hypothesize impact increase systemic exposure atenolol lead increase risk adverse metabolic effect atenolol therapy hypertension . This accomplished 24-hour pharmacokinetic ( PK ) study oral glucose tolerance test hypertensive patient take chronic atenolol 100 mg daily .</brief_summary>
	<brief_title>Atenolol Exposure Risk Adverse Metabolic Responses Beta Blockers</brief_title>
	<detailed_description>The current study sub-study Pharmacogenomic Evaluation Antihypertensive Responses ( PEAR - NCT00246519 ) . The primary objective pharmacokinetic ( PK ) study investigate correlation atenolol Cp hypertriglyceridemia insulin sensitivity mild moderate hypertensive patient 6-8 week atenolol treatment . Participants undergo PK study atenolol 100 mg daily least 4 week atenolol therapy ( 50 mg 100 mg ) â‰¥ 7 week . They undergo two hour Oral Glucose Tolerance Test ( OGTT ) , 1 hour atenolol dosing . Blood drawn 12 time point 24 hour . Atenolol Cp measure 12 blood sample correlate glucose/insulin measure OGTT .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>Subjects PEAR atenolol 100 mg daily invite participate Other inclusion criterion PEAR Patients BMI &gt; 35 kg/m2 exclude Other exclusion criterion PEAR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Keywords National Institute General Medical Sciences</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Adverse metabolic effect</keyword>
	<keyword>Beta blocker</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Atenolol</keyword>
	<keyword>New onset diabetes</keyword>
	<keyword>Pharmacokinetic study</keyword>
	<keyword>Oral glucose tolerance test</keyword>
</DOC>